Study of Pamidronate for the Prevention of Heterotopic Ossification
Information source: University Hospital, Basel, Switzerland
Information obtained from ClinicalTrials.gov on August 08, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heterotopic Ossification
Intervention: Pamidronate (AREDIA) (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University Hospital, Basel, Switzerland Official(s) and/or principal investigator(s):
philipp schuetz, MD, Principal Investigator, Affiliation: University Hospital Basel
Christian Meier, MD, Study Director, Affiliation: University Hospital in Basel
Overall contact:
philipp d schuetz, MD, Phone: 0041 76 569 2683, Email: PHILIPP@SCHUETZ.COM
Summary
The purpose of this study is to determine whether Bisphosphonates in comparison to radiation
therapy are effective in the prophylaxis and treatment of heterotopic ossification in high
risk patients.
Clinical Details
Official title: Study Into the Effect of Pamidronate for the Prevention of Heterotopic Ossification in High-Risk Patients: A Randomized Controlled Trial
Study design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Primary outcome: Primary endpoint is the radiological Heterotopic Ossification recurrence rate.
Secondary outcome: Secondary endpoints are the clinical, functional and biochemical outcome (as assessed by several clinical and laboratory markers).
Detailed description:
BACKGROUND: The acquired form of heterotopic ossification (HO) is the most common type of
extraskeletal ossification and usually precipitated by a trauma such as total hip
arthroplasty [THA] or spinal cord injury. After THA the incidence of HO is as high as 50%,
but may reach up to 90% in high risk populations leading to severe functional impairment with
ankylotic loss of joint mobility. Nonsteroidal anti-inflammatory drugs (NSAIDs) and external
radiation have been used in preventing HO. Specifically, patients with surgical resection of
HO at the hip have a high postoperative relapsing rate. Best results were observed after
prophylactic radiation treatment with disease recurrence in 33-45% of patients. Data on the
effect of bisphosphonates in the prevention of postoperative HO are scarce and mainly limited
to the use of the first generation bisphosphonate etidronate. In a retrospective
observational study we observed a marked beneficial effect of pamidronate infusions: none of
the high risk patients with established HO undergoing surgical removal presented with disease
recurrence.
AIM: We therefore aim to prospectively confirm our findings and to evaluate the efficacy of
pamidronate for the prevention of recurrent HO after surgical removal of ipsilateral HO.
Clinical, biochemical and radiological treatment outcome will be compared to standard
clinical practice using preoperative external radiation.
ENDPOINTS: Primary endpoint is the radiological HO recurrence rate. Secondary endpoints are
the clinical, functional and biochemical outcome (as assessed by several clinical and
laboratory markers).
METHODS: This prospective, randomized trial will be carried out at the University Hospital in
Basel/Buderholz in collaboration with the Orthopedic Clinic of the Swiss Paraplegic Centre in
Nottwil. Patients who are admitted to the one of the participating orthopedic clinics for
removal of HO at the hip will be included in the study. A total number of 40 consecutive
patients will be recruited (recruitment phase 24 months) and randomized in a "bisphosphonate
group", treated with peri- and postoperative pamidronate infusions (1. 0 mg/kg/day for 3 days)
and in a "radiation group", treated with external radiation with a single dose of 7 Gy within
24 hours prior to surgical intervention. Additionally, both groups will be treated with
NSAIDs for 14 days.
EXPECTED RESULTS: We hypothesize that in treating patients at risk, therapy with pamidronate
will be superior in reducing the recurrence rate of established HO as compared to external
radiation after surgical resection.
SIGNIFICANCE: Because of the high prevalence in selected risk patients and significant
morbidity of HO, this study will offer potential for improving the management of HO. Our
study is targeting patients with high risk to develop HO were highly effective prevention is
still lacking. Furthermore, a diagnostic marker to identify patients at risk to develop HO
would optimize disease management and would allow for early, more successful treatment.
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Consecutive patients with established HO (Brooker grade III-IV), hospitalized for
resection of HO lesions
Exclusion criteria:
- Age <20 years
- Vitamin D deficiency (25OH-Vitamin D <30 ng/ml)
- Renal insufficiency (Clearance <50 ml/min)
- Intolerance of bisphosphonates
- Unable to provide informed consent
Locations and Contacts
philipp d schuetz, MD, Phone: 0041 76 569 2683, Email: PHILIPP@SCHUETZ.COM
University Hospital in Basel, Basel 4052, Switzerland; Recruiting
philipp schuetz, MD, Phone: 0041 76 569 26 83, Email: schuetzp@uhbs.ch
Beat Mueller, Prof, Principal Investigator
Walter Dick, Prof, Principal Investigator
Marius Kraenzlin, PD DR. med., Sub-Investigator
Patrick , Moulin, Dr. med., Sub-Investigator
Niklaus Friederich,, Prof., Sub-Investigator
Christine , Landmann, Prof., Sub-Investigator
Additional Information
Related publications: Schuetz P, Mueller B, Christ-Crain M, Dick W, Haas H. Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive cases. Spinal Cord. 2005 Oct;43(10):604-10.
Starting date: June 2005
Ending date: June 2010
Last updated: November 5, 2007
|
